Camblong Jurgi sold $209K of SOPH

Camblong Jurgi (Executive Chairman) sold 28,500 shares of SOPHiA GENETICS SA (SOPH) at an average of $7.34 ($7.23–$7.61, $0.21M total) across 2 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Camblong Jurgi
Published Aug 10, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

Traders may briefly monitor for follow-on insider activity, but the 10b5-1 pre-arranged nature generally limits interpretive value.

02

Market read

A routine 10b5-1 insider sale for about $209K is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

The filing does not disclose reasons for the sale, and the weighted-average price range ($7.2270 to $7.6081) may reflect normal execution timing rather than a view on valuation.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-08-10

Background

This is an SEC Form 4 insider transaction for SOPHiA GENETICS, reported by executive chairman Camblong Jurgi.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

SEC Form 4 shows SOPHiA GENETICS executive chairman Camblong Jurgi sold 28,500 shares for about $209K across two trades.

Expected impact

Likely minimal, unless traders interpret the sale as a sentiment read-through despite the 10b5-1 structure.

Evidence & confidence

Form 4 details an open-market sale and explicitly notes a pre-arranged 10b5-1 plan, which typically reduces the informational content versus discretionary selling.

Market effects

No clear sector read-through from a single, small-to-moderate insider sale with 10b5-1 context.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven under the 10b5-1 plan and should not be treated as a bearish fundamental signal.

Key entities

  • SOPHiA GENETICS SA

    Subject of the Form 4 insider transaction; executive chairman sold shares under a 10b5-1 plan.

  • Camblong Jurgi

    Executive Chairman and reporting person who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September